Melanoma molecular classes and prognosis in the postgenomic era

Elisa Tremante; Agnese Ginebri; Elisa Lo Monaco; Pasquale Frascione; Franco Di Filippo; Irene Terrenato; Maria Benevolo; Marcella Mottolese; Edoardo Pescarmona; Paolo Visca; Pier Giorgio Natali; Patrizio Giacomini

doi:10.1016/S1470-2045(12)70003-7

Melanoma molecular classes and prognosis in the postgenomic era

Elisa Tremante, Agnese Ginebri, Elisa Lo Monaco, Pasquale Frascione, Franco Di Filippo, Irene Terrenato, Maria Benevolo, Marcella Mottolese, Edoardo Pescarmona, Paolo Visca, Pier Giorgio Natali, Patrizio Giacomini

Research output: Contribution to journal › Article

Abstract

Gene expression profiling is a powerful method to classify human tumours on the basis of biological aggressiveness, response to therapy, and outcome for the patient, but its application in melanoma lags behind that of other cancers. From more than 100 articles available on the topic, we selected 14 focusing on patients' outcome. We review and briefly discuss salient findings, and list ten reasons why melanoma molecular classes are not yet used in clinical diagnosis and prognosis. The available evidence suggests that we are on the verge of creating a framework for the use of melanoma molecular classes in prognosis, but so far there is little consensus to put together informative diagnostic and prognostic gene sets.

Original language	English
Journal	The Lancet Oncology
Volume	13
Issue number	5
DOIs	https://doi.org/10.1016/S1470-2045(12)70003-7
Publication status	Published - May 2012

ASJC Scopus subject areas

Oncology

Access to Document

10.1016/S1470-2045(12)70003-7

Fingerprint Dive into the research topics of 'Melanoma molecular classes and prognosis in the postgenomic era'. Together they form a unique fingerprint.

Cite this

Tremante, E., Ginebri, A., Lo Monaco, E., Frascione, P., Di Filippo, F., Terrenato, I., Benevolo, M., Mottolese, M., Pescarmona, E., Visca, P., Natali, P. G., & Giacomini, P. (2012). Melanoma molecular classes and prognosis in the postgenomic era. The Lancet Oncology, 13(5). https://doi.org/10.1016/S1470-2045(12)70003-7

Melanoma molecular classes and prognosis in the postgenomic era. / Tremante, Elisa; Ginebri, Agnese; Lo Monaco, Elisa; Frascione, Pasquale; Di Filippo, Franco; Terrenato, Irene; Benevolo, Maria ; Mottolese, Marcella; Pescarmona, Edoardo; Visca, Paolo; Natali, Pier Giorgio; Giacomini, Patrizio.

In: The Lancet Oncology, Vol. 13, No. 5, 05.2012.

Research output: Contribution to journal › Article

@article{b90eb7cc02fd4e9e85cf659e6961d668,

title = "Melanoma molecular classes and prognosis in the postgenomic era",

abstract = "Gene expression profiling is a powerful method to classify human tumours on the basis of biological aggressiveness, response to therapy, and outcome for the patient, but its application in melanoma lags behind that of other cancers. From more than 100 articles available on the topic, we selected 14 focusing on patients' outcome. We review and briefly discuss salient findings, and list ten reasons why melanoma molecular classes are not yet used in clinical diagnosis and prognosis. The available evidence suggests that we are on the verge of creating a framework for the use of melanoma molecular classes in prognosis, but so far there is little consensus to put together informative diagnostic and prognostic gene sets.",

author = "Elisa Tremante and Agnese Ginebri and {Lo Monaco}, Elisa and Pasquale Frascione and {Di Filippo}, Franco and Irene Terrenato and Maria Benevolo and Marcella Mottolese and Edoardo Pescarmona and Paolo Visca and Natali, {Pier Giorgio} and Patrizio Giacomini",

year = "2012",

month = may,

doi = "10.1016/S1470-2045(12)70003-7",

language = "English",

volume = "13",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "5",

}

TY - JOUR

T1 - Melanoma molecular classes and prognosis in the postgenomic era

AU - Tremante, Elisa

AU - Ginebri, Agnese

AU - Lo Monaco, Elisa

AU - Frascione, Pasquale

AU - Di Filippo, Franco

AU - Terrenato, Irene

AU - Benevolo, Maria

AU - Mottolese, Marcella

AU - Pescarmona, Edoardo

AU - Visca, Paolo

AU - Natali, Pier Giorgio

AU - Giacomini, Patrizio

PY - 2012/5

Y1 - 2012/5

N2 - Gene expression profiling is a powerful method to classify human tumours on the basis of biological aggressiveness, response to therapy, and outcome for the patient, but its application in melanoma lags behind that of other cancers. From more than 100 articles available on the topic, we selected 14 focusing on patients' outcome. We review and briefly discuss salient findings, and list ten reasons why melanoma molecular classes are not yet used in clinical diagnosis and prognosis. The available evidence suggests that we are on the verge of creating a framework for the use of melanoma molecular classes in prognosis, but so far there is little consensus to put together informative diagnostic and prognostic gene sets.

AB - Gene expression profiling is a powerful method to classify human tumours on the basis of biological aggressiveness, response to therapy, and outcome for the patient, but its application in melanoma lags behind that of other cancers. From more than 100 articles available on the topic, we selected 14 focusing on patients' outcome. We review and briefly discuss salient findings, and list ten reasons why melanoma molecular classes are not yet used in clinical diagnosis and prognosis. The available evidence suggests that we are on the verge of creating a framework for the use of melanoma molecular classes in prognosis, but so far there is little consensus to put together informative diagnostic and prognostic gene sets.

UR - http://www.scopus.com/inward/record.url?scp=84860424628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860424628&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(12)70003-7

DO - 10.1016/S1470-2045(12)70003-7

M3 - Article

C2 - 22554548

AN - SCOPUS:84860424628

VL - 13

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 5

ER -